Combined Bigpharma Dealmaking and Agreements Handbook 2007

Summary

The Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.

The Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.

Description

The combined Bigpharma Dealmaking and Agreements Handbook 2007 provides the entire content of both reports at a great discounted price.

Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in 2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-6 according to reported deal size.

Chapter 5 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner. Chapter 6 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities.

The main body of the report is provided in chapter 7 and 8. Firstly, a series of matrices provide a cross reference for each bigpharma company versus therapy area with respect to marketed and pipeline activity, partnering interests, and partnering activity in the last two years. Secondly, in-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. Each profile also includes in-depth contact information for individuals within the business development function.

In addition, each company profile provides a listing of deal contract documents available in the public domain, each of which can be obtained from CurrentPartnering, either individually or as part of a contract set. See each company profile for further details.

Key benefits

Bigpharma Dealmaking Handbook 2007 provides the user with the following key benefits:

A comprehensive overview of the partnering activities and interests of the leading fifty biopharma companies

Identify prospective partner companies by analyzing their dealmaking activity and interests

Undertake initial due diligence to assess suitability of partner companies

Make direct contact with over 1,300 named business development executives

Identify over 1,000 actual contract agreements entered into by the company and its partner companies

Understand the key deal terms the company has agreed in previous deals

Report scope

Bigpharma Dealmaking Handbook 2007 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.

Bigpharma Dealmaking Handbook 2007 includes:

The tools to enable effective and efficient partnering with bigpharma

Detailed partnering activity and interests profiles for the leading fifty bigpharma companies

Direct contact information for over 1,300 bigpharma dealmakers

Listing of over 1,000 contract documents between bigpharma and partner companies

The leading M&A and partnering deals by value 2005-6

Most active M&A and partnering dealmakers 2005-6

Guidelines on how to submit partnering opportunities to bigpharma

The leading partnering resources and networking events

The Bigpharma Dealmaking Handbook 2007 provides a comprehensive profile for each of the fifty bigpharma companies, including:

Detailed company profile

In-depth marketed and pipeline activity of each company

Partnering interests statement and therapy focus

Partnering activity for 2005-2006

Activity by deal type

Activity by phase of development

Activity by therapeutic area

List of recent partner companies

Direct contact information for dealmakers

General company and partnering contact information

List of contract documents available# to allow analysis of bigpharma deal terms

#Can be purchased individually, as part of a contract set, of through purchase of the sister report Bigpharma Agreement Handbook – all available from CurrentPartnering.

Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.

Understanding the flexibility of a prospective partner’s negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 1,000 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners.

Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

The main body of the report is provided in chapter 5. Each of the top 50 bigpharma companies is provided with a brief summary followed by a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type – therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.

Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. In addition, the contract document collection can be used offline and is available on CD-Rom.

Report scope

Bigpharma Agreements Handbook 2007 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.

Bigpharma Agreements Handbook 2007 includes:

The tools to enable effective and efficient preparation for partnering negotiation with bigpharma

Detailed partnering activity and interests profiles for the leading fifty bigpharma companies

Listing of over 1,000 contract documents between bigpharma and partner companies

The leading M&A and partnering deals by value 2005-6

Most active M&A and partnering dealmakers 2005-6

The leading partnering resources

For each company in Bigpharma Agreements Handbook 2007, the available contracts are listed by deal type, including:

Co-development

Co-marketing

Co-promotion

Collaborative R&D

Development

Distribution

Joint venture

Licensing

M&A

Manufacturing

Marketing

Promotion

Research

Supply

The Bigpharma Agreements Handbook 2007 provides comprehensive access to available contract documents for each of the fifty bigpharma companies. Analyzing actual company agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subscontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Date of publication: September 2007 Total pages (combined reports): 748 Publisher: CurrentPartnering Formats available: PDF,
Table of Contents
Price: $3,950.00 / GBP1,975.00